ReviewFrontiers in oncology2024

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.

Blaine Brower et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.